7ZLK image
Deposition Date 2022-04-15
Release Date 2022-09-21
Last Version Date 2025-07-02
Entry Detail
PDB ID:
7ZLK
Keywords:
Title:
AMC009 SOSIPv5.2 in complex with Fabs ACS114 and ACS122
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.99 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:AMC009 SOSIPv5.2 envelope glycoprotein gp120
Chain IDs:A, C, E (auth: D)
Chain Length:482
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Molecule:AMC009 SOSIPv5.2 envelope glycoprotein gp41
Chain IDs:B, D (auth: E), F
Chain Length:154
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Molecule:ACS114 heavy chain
Chain IDs:G (auth: H), K (auth: O), M (auth: Q)
Chain Length:120
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:ACS114 light chain
Chain IDs:H (auth: L), L (auth: P), N (auth: R)
Chain Length:112
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:ACS122 heavy chain
Chain IDs:I (auth: M), O (auth: S)
Chain Length:124
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:ACS122 light chain
Chain IDs:J (auth: N), P (auth: T)
Chain Length:108
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation

Abstact

Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subtypes and are able to prevent HIV-1 infection in animal models. However, bNAbs are extremely difficult to induce by vaccination. Defining the developmental pathways towards neutralization breadth can assist in the design of strategies to elicit protective bNAb responses by vaccination. Here, HIV-1 envelope glycoproteins (Env)-specific IgG+ B cells were isolated at various time points post infection from an HIV-1 infected elite neutralizer to obtain monoclonal antibodies (mAbs). Multiple antibody lineages were isolated targeting distinct epitopes on Env, including the gp120-gp41 interface, CD4-binding site, silent face and V3 region. The mAbs each neutralized a diverse set of HIV-1 strains from different clades indicating that the patient's remarkable serum breadth and potency might have been the result of a polyclonal mixture rather than a single bNAb lineage. High-resolution cryo-electron microscopy structures of the neutralizing mAbs (NAbs) in complex with an Env trimer generated from the same individual revealed that the NAbs used multiple strategies to neutralize the virus; blocking the receptor binding site, binding to HIV-1 Env N-linked glycans, and disassembly of the trimer. These results show that diverse NAbs can complement each other to achieve a broad and potent neutralizing serum response in HIV-1 infected individuals. Hence, the induction of combinations of moderately broad NAbs might be a viable vaccine strategy to protect against a wide range of circulating HIV-1 viruses.

Legend

Protein

Chemical

Disease

Primary Citation of related structures